Tab-cel Returns to FDA With a Rebuilt Evidence Package
Pierre Fabre, supported by Atara Biotherapeutics, resubmitted the U.S. biologics license application for tabelecleucel in adults and children at least two years old with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease after at…
